RELMADA THERAPEUTICS, INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Relmada Therapeutics, Inc.
NEW YORK, NY – May 8, 2023 – Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQ: RLMD) for violations of the federal securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Relmada announced the results of its RELIANCE III study of drug REL-1017 on October 13, 2022. The Company disclosed that the trial did not reach its primary endpoint, and that “paradoxical results were observed in certain study sites, where [the] placebo dramatically outperformed REL-1017.”
Based on this news, shares of Relmada dropped by almost 80% on the next day.
If you purchased Relmada Therapeutics, Inc. shares and suffered losses, please call Gregory Stone at (800) 575-0735 or (212) 545-4774 or email firstname.lastname@example.org.
Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this investigation or have any questions regarding your rights and interests in this matter, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at email@example.com, or visit our website at www.whafh.com.
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Tel: (800) 575-0735 or (212) 545-4774